Thermo Fisher Scientific Aflibercept Humanized Recombinant Human Monoclonal Antibody

Thermo Fisher Scientific Aflibercept Humanized Recombinant Human Monoclonal Antibody

Applications

• ELISA

Tested Dilution: 1:5,000–1:10,000

Product Specifications

Product Specific Information

• Endotoxin level < 0.01 EU/µg (LAL method)
• Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Store at 2–8°C for one week.
• Store at -20 to -80°C for twelve months from the date of receipt.

Target Information

Biosimilars targeting aflibercept, such as Yesafili, Opuviz, and Pavblu, function by inhibiting vascular endothelial growth factor (VEGF) pathways, crucial for angiogenesis and vascular permeability.
These biosimilars emulate the activity of aflibercept, a recombinant fusion protein that combines portions of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) with an immunoglobulin G (IgG) Fc fragment, effectively acting as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF).
By binding to these growth factors, the biosimilars prevent their interaction with VEGF receptors on the surface of endothelial cells, thereby inhibiting pathological angiogenesis and increased vascular permeability seen in conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Clinical studies have shown that biosimilars such as SCD411, SB15, and QL1207 demonstrate comparable efficacy and safety to the reference product, aflibercept, in these indications, offering alternative treatment options that meet rigorous equivalency standards set by regulatory bodies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.